Dapagliflozin (BMS-512148, BMS512148)，又称达格列净、达帕格列净或达格列嗪，是一种抗糖尿病药物，体内耐受性好，是竞争性葡萄糖协同转运蛋白2 (SGLT2)的抑制剂，EC₅₀为1.1 nM，抑制葡萄糖的重新收，促进葡萄糖经尿液排出，改善不依赖于胰岛素的血糖控制。

参考文献

1.Pedersen MG, et al. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. Sci Rep. 2016 Aug 18;6:31214.

2.Chiba Y, et al. Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice. PLoS One. 2016 Mar 10;11(3):e0150756.

3.Chang YK, et al. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury. PLoS One. 2016 Jul 8;11(7):e0158810.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。